Translate Bio (NASDAQ:TBIO) Sees Unusually-High Trading Volume

Shares of Translate Bio Inc (NASDAQ:TBIO) saw strong trading volume on Friday . 1,378,700 shares changed hands during mid-day trading, an increase of 538% from the previous session’s volume of 216,146 shares.The stock last traded at $8.13 and had previously closed at $7.94.

A number of analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Translate Bio in a research report on Thursday, August 1st. Jefferies Financial Group assumed coverage on Translate Bio in a research report on Monday, July 22nd. They issued a “buy” rating and a $20.00 price objective for the company. Roth Capital assumed coverage on Translate Bio in a research report on Tuesday, June 18th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Zacks Investment Research upgraded Translate Bio from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $22.75.

The stock has a 50-day simple moving average of $9.54 and a 200 day simple moving average of $9.63. The company has a debt-to-equity ratio of 1.15, a quick ratio of 7.67 and a current ratio of 7.67. The company has a market cap of $420.33 million, a P/E ratio of -2.23 and a beta of 1.01.



Translate Bio (NASDAQ:TBIO) last posted its earnings results on Wednesday, July 31st. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.09). The company had revenue of $1.17 million for the quarter, compared to the consensus estimate of $1.73 million. Translate Bio had a negative return on equity of 84.22% and a negative net margin of 2,696.98%. Sell-side analysts anticipate that Translate Bio Inc will post -1.96 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in shares of Translate Bio by 130.2% during the 4th quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after buying an additional 555,635 shares during the period. Aevitas Wealth Management Inc. bought a new position in shares of Translate Bio during the 1st quarter worth approximately $58,000. Bailard Inc. bought a new position in shares of Translate Bio during the 1st quarter worth approximately $135,000. Northern Trust Corp lifted its position in shares of Translate Bio by 12.4% during the 4th quarter. Northern Trust Corp now owns 111,339 shares of the company’s stock worth $835,000 after buying an additional 12,242 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Translate Bio during the 4th quarter worth approximately $118,000. Institutional investors and hedge funds own 57.90% of the company’s stock.

About Translate Bio (NASDAQ:TBIO)

Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.

Featured Article: Buyback

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.